Clinical Hold on Fulcrum’s Sickle Cell Hopeful Triggered by Hematologic Malignancies Profile

In its full year 2022 financial report, released Thursday, Fulcrum Therapeutics revealed further details regarding the full clinical hold placed on FTX-6058 in February.